ST Pharm is ramping up its global oligonucleotide contract development and manufacturing organization (CDMO) business, leveraging its newly operational second oligonucleotide facility. The company’s strategy is to bolster partnerships with existing clients while aggressively pursuing new projects, capitalizing on its expanded production capabilities.
ST Pharm is currently engaged in business meetings with global pharmaceutical and biotech companies at CPHI Worldwide 2026, the world’s largest pharmaceutical exhibition, taking place in Milan, Italy from October 6-8.
During this event, ST Pharm is showcasing its core competencies in oligonucleotide CDMO services, reviewing ongoing projects with current clients, and exploring new business opportunities. The company is also holding discussions with clients in the small molecule active pharmaceutical ingredient (API) sector to negotiate potential new projects and business expansion.
In response to the growing global demand for oligonucleotide CDMO services, ST Pharm completed construction of its second oligonucleotide facility last year, which became fully operational this year. This new facility is equipped with a range of production lines, from small to large scale, enabling the company to meet diverse production needs across all stages, from early clinical trials to full commercialization.
ST Pharm aims to leverage its expanded production capacity to meet increased demand from existing clients while simultaneously securing new customers and projects to drive growth in its CDMO business.
Since 2016, ST Pharm has been a regular participant at CPHI alongside Dong-A ST, consistently expanding its network within the global pharmaceutical and biotech industry. This year’s event continues to prioritize fostering collaborations with international companies.
A spokesperson for ST Pharm stated that it’s highlighting the oligonucleotide CDMO production capabilities and global competitiveness. Building on the RNA-based technology and CDMO expertise, it intends to deepen the relationships with existing global partners while actively pursuing new business opportunities.
Meanwhile, ST Pharm reported a significant boost in its second-quarter performance, driven by the expansion of both oligonucleotide and small molecule commercialization projects.
The company posted consolidated revenues of 108.5 billion KRW (approximately 80.6 million USD) and an operating profit of 18.3 billion KRW (about 13.6 million USD) for the quarter. These figures represent year-over-year increases of 58.9% and 41.7%, respectively. Net profit surged to 13.2 billion KRW (roughly 9.8 million USD), marking a substantial 145.0% increase from the previous year.
For the first half of the year, ST Pharm’s cumulative revenues reached 175.4 billion KRW (approximately 130.4 million USD), with an operating profit of 29.8 billion KRW (about 22.2 million USD). These results reflect impressive year-over-year growth of 45.4% and 114.0%, respectively.